Merrimack Pharmaceuticals traded at $14.73 this Tuesday April 9th, increasing $0.03 or 0.20 percent since the previous trading session. Looking back, over the last four weeks, Merrimack Pharmaceuticals gained 0.48 percent. Over the last 12 months, its price rose by 15.98 percent. Looking ahead, we forecast Merrimack Pharmaceuticals to be priced at 14.41 by the end of this quarter and at 13.48 in one year, according to Trading Economics global macro models projections and analysts expectations.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.